EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Therapeutic Efficacy of Silymarin, Vitamin E, and Essential Phospholipid Combination Therapy on Hepatic Steatosis, Fibrosis, and Metabolic Parameters in MASLD Patients: A Prospective Clinical Study

Dan-Ionuț Gheonea, Cristina Tocia, Victor-Mihai Sacerdoțianu iD, Alexandra-Georgiana Bocioagă, Irina-Paula Doica iD, Nicolae Cătălin Manea, Adina Turcu-Știolică iD, Carmen-Nicoleta Oancea iD, Eugen Dumitru iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26125427 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Dan-Ionuț Gheonea und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania. Hauptthemen laut MEDLINE: Vitamin E, Silymarin, Phospholipids, Liver Cirrhosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SUNWAVE PHARMA, University of Medicine and Pharmacy of Craiova, Romania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease globally, and current estimates indicate an increase in incidence and prevalence in the general population. The design of the prospective study was to evaluate the response of patients with MASLD to an original formula consisting of silymarin, vitamin E, and essential phospholipids. In total, 200 patients were initially enrolled in the study and a total of 190 who participated in all four visits were included in our analysis. During the visits, liver function tests, lipid profiles, blood glucose level, fibrosis, and steatosis values and grades were assessed. From baseline, visit 0, to month 6th, visit III, a statistically significant difference (p-value < 0.0001) was observed in the reduction in ALT, AST, GGT, ALP, TG, total cholesterol, and blood glucose levels. There was a significant decrease in the fibrosis value from the first visit to the last visit (p = 0.002). Even though administered separately, silymarin, essential phospholipids, and vitamin E have established their efficacy in MASLD, this study demonstrates that their combination produces an indubitable effect on liver steatosis, even in a short cure of 6 months, and it can be proposed due to it having no adverse effects on patients with MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vitamin ESilymarinPhospholipidsLiver CirrhosisFatty LiverHumansMaleFemaleMiddle AgedProspective StudiesAdultAgedTreatment OutcomeDrug Therapy, CombinationLiver Function Tests

Stichwörter der Autor:innen

MASLDVCTEsilymarin

Substanzen

Vitamin ESilymarinPhospholipids

Autor:innen und Institutionen

  • Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania.
  • Gastroenterology Department, "Sf. Apostol Andrei" Clinical Emergency County Hospital, 145 Tomis Blvd., 900591 Constanta, Romania.
  • Faculty of Medicine, Ovidius University of Constanta, 1 Universitatii Street, 900470 Constanta, Romania.
  • Department of Biochemistry, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
  • Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania.
  • Biostatistics Department, Faculty of Pharmacy, University of Medicine and Pharmacy Craiova, Petru Rares Street No 2-4, 200349 Craiova, Romania.

ORCID-Profile: Victor-Mihai Sacerdoțianu, Irina-Paula Doica, Adina Turcu-Știolică, Carmen-Nicoleta Oancea, Eugen Dumitru

Förderung

  • SUNWAVE PHARMA
  • University of Medicine and Pharmacy of Craiova, Romania

Zitieren

APA

Gheonea, D. I., Tocia, C., Sacerdoțianu, V. M., Bocioagă, A. G., Doica, I. P., Manea, N. C., Turcu-Știolică, A., Oancea, C. N., & Dumitru, E. (2025). Therapeutic Efficacy of Silymarin, Vitamin E, and Essential Phospholipid Combination Therapy on Hepatic Steatosis, Fibrosis, and Metabolic Parameters in MASLD Patients: A Prospective Clinical Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125427

Vancouver

Gheonea DI, Tocia C, Sacerdoțianu VM, Bocioagă AG, Doica IP, Manea NC, et al. Therapeutic Efficacy of Silymarin, Vitamin E, and Essential Phospholipid Combination Therapy on Hepatic Steatosis, Fibrosis, and Metabolic Parameters in MASLD Patients: A Prospective Clinical Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125427

BibTeX
@article{Gheonea2025,
  author = {Gheonea, Dan-Ionuț and Tocia, Cristina and Sacerdoțianu, Victor-Mihai and Bocioagă, Alexandra-Georgiana and Doica, Irina-Paula and Manea, Nicolae Cătălin and Turcu-Știolică, Adina and Oancea, Carmen-Nicoleta and Dumitru, Eugen},
  title = {Therapeutic Efficacy of Silymarin, Vitamin E, and Essential Phospholipid Combination Therapy on Hepatic Steatosis, Fibrosis, and Metabolic Parameters in MASLD Patients: A Prospective Clinical Study},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26125427}
}
Kostenlos starten →